STOCK TITAN

AccuStem Sciences, Inc. Announces Chairman Purchase of Shares

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

AccuStem Sciences (OTCQB: ACUT), a clinical stage diagnostics company focused on cancer patient outcomes, has announced that its Board Chairman, Gabriele Cerrone, has acquired an additional 100,000 ACUT shares through open market purchases. Following this transaction, Cerrone's total shareholding has increased to 4,719,957 shares.

Loading...
Loading translation...

Positive

  • Chairman's increased stake demonstrates confidence in company
  • Significant insider ownership with Chairman holding over 4.7M shares

Negative

  • Company still trades on OTCQB market rather than major exchange

News Market Reaction

+15.09%
1 alert
+15.09% News Effect

On the day this news was published, ACUT gained 15.09%, reflecting a significant positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

LONDON and PHOENIX, Jan. 03, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced that its Chairman of the Board, Mr. Gabriele Cerrone, has notified the Company that he has recently purchased an additional 100,000 ACUT shares in the open market. This brings his total holding to 4,719,957 shares.

About AccuStem

AccuStem is a clinical stage diagnostics company dedicated to optimizing outcomes and quality of life for all patients with cancer. We plan to drive innovation in healthcare by offering proprietary molecular testing that addresses unmet clinical needs from cancer screening through treatment and monitoring. By interrogating novel disease pathways, such as tumor “stemness,” we believe our tools will help care teams better understand the biology of each patient’s cancer, leading to more informed decision making. For more information, please visit www.accustem.com.

Investor and Media Contact:
Wendy Blosser
Email: investors@accustem.com


FAQ

How many ACUT shares did AccuStem's Chairman purchase in January 2025?

AccuStem's Chairman Gabriele Cerrone purchased 100,000 additional ACUT shares in the open market in January 2025.

What is the total number of ACUT shares held by Chairman Gabriele Cerrone?

Following his recent purchase, Chairman Gabriele Cerrone holds a total of 4,719,957 ACUT shares.

What stock exchange does AccuStem Sciences (ACUT) trade on?

AccuStem Sciences (ACUT) trades on the OTCQB market.

What type of company is AccuStem Sciences (ACUT)?

AccuStem Sciences is a clinical stage diagnostics company focused on improving outcomes for cancer patients.
ACCUSTEM SCIENCES INC

OTC:ACUT

ACUT Rankings

ACUT Latest News

ACUT Latest SEC Filings

ACUT Stock Data

25.72M
10.00M
37.77%
Biotechnology
Healthcare
Link
United States
New York